Search

The virus family Reoviridae comprises a diverse group of nonenveloped, segmented, double-stranded RNA viruses classified into 10 genera. Members of the genus Orthoreovirus are classified as fusogenic or nonfusogenic, depending [...]

We describe the timely adaption of both published WHO E‐gene protocol and commercially available LightMix Modular E‐gene assay to the test platform (ABI 7900 Fast real‐time analyzer and TaqMan Fast One‐step Virus Master Mix) available in an accredited tertiary hospital laboratory with an on‐going evaluation to ensure the provision of quality service within the time constraint. The LightMix Modular E‐gene was slightly more sensitive when compared to the WHO E‐gene, both analytically and diagnostically. The assay was recommended for screening of SARS‐CoV‐2 infection. With the availability of technically competent staff through continuous training, the provision of round‐the‐clock service is feasible despite the test is of high complexity. The thermal cycling duration of the adapted LightMix E‐gene and WHO E‐gene is shortened by half and one hour respectively and allows the number of runs to double when 24‐h round‐the‐clock service is provided. An increase in testing capacity could support surges in testing demand, which is essential to control the current SARS‐CoV‐2 pandemic, to prevent potential overwhelming of the healthcare system, and to optimize utilization of the isolation beds. Highlights: We described timely adaption of published WHO E‐gene protocol and commercially available LightMix Modular E‐gene assay for emergency use.Both adapted protocols were compared and the LightMix Modular E‐gene was found slightly more sensitive than the WHO E‐gene.The adapted LightMix Modular E‐gene assay is suitable for initial screening. [ABSTRACT FROM AUTHOR]